Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Buy
58
SMMT Quote, Financials, Valuation and Earnings
Last price:
$23.61
Seasonality move
:
12.43%
Day range:
$23.04 - $26.97
52-week range:
$2.10 - $36.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18,120.38x
P/B ratio:
45.75x
Volume:
13.1M
Avg. volume:
5M
1-year change:
524.61%
Market cap:
$17.8B
Revenue:
--
EPS (TTM):
-$0.32
Analysts' Opinion
-
Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.19, Summit Therapeutics has an estimated upside of 54.24% from its current price of $24.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing -24.45% downside risk from its current price of $24.11.
Fair Value
-
According to the consensus of 6 analysts, Summit Therapeutics has 54.24% upside to fair value with a price target of $37.19 per share.
SMMT vs. S&P 500
-
Over the past 5 trading days, Summit Therapeutics has underperformed the S&P 500 by -7.05% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Summit Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Summit Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Summit Therapeutics reported revenues of --.
Earnings Growth
-
Summit Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Summit Therapeutics reported earnings per share of -$0.09.
Enterprise value:
17.4B
EV / Invested capital:
--
Price / LTM sales:
18,120.38x
EV / EBIT:
--
EV / Revenue:
18,172.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-122.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$63.6M | -$609.7M | -$226M | -$557.2M | -$80.6M | |
| EBITDA | -$72.5M | -$598.3M | -$212.5M | -$33.7M | -$61.1M | |
| Diluted EPS | -$0.41 | -$1.49 | -$0.32 | -$0.01 | -$0.09 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $87.7M | $97.3M | $656.7M | $189.7M | $423.8M | |
| Total Assets | $102.5M | $113.4M | $664.2M | $202.9M | $435.6M | |
| Current Liabilities | $19.9M | $25.6M | $38.8M | $20.4M | $41.7M | |
| Total Liabilities | $23M | $30.1M | $537.5M | $125.3M | $46.8M | |
| Total Equity | $79.5M | $83.3M | $126.7M | $77.7M | $388.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.6M | -$76.8M | -$142.1M | -$19.5M | -$48.7M | |
| Cash From Investing | -$624K | -$587.8M | -$205.3M | $60.6M | $83.5M | |
| Cash From Financing | $620.2M | $86.5M | $381.2M | $6.3M | -$23.6M | |
| Free Cash Flow | -$42.2M | -$76.9M | -$142.2M | -$19.5M | -$48.7M | |
SMMT
Sector
Market Cap
$17.8B
$34.4M
Price % of 52-Week High
65.32%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
524.61%
-39.44%
Beta (5-Year)
-0.455
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.22
200-day SMA
Buy
Level
$18.45
Bollinger Bands (100)
Buy
Level
17.19 - 23.33
Chaikin Money Flow
Buy
Level
278.7M
20-day SMA
Buy
Level
$22.94
Relative Strength Index (RSI14)
Buy
Level
50.99
ADX Line
Buy
Level
25.04
Williams %R
Neutral
Level
-60.5742
50-day SMA
Buy
Level
$21.18
MACD (12, 26)
Buy
Level
2.20
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
586.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Stock Forecast FAQ
In the current month, SMMT has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SMMT average analyst price target in the past 3 months is $37.19.
-
Where Will Summit Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Summit Therapeutics share price will rise to $37.19 per share over the next 12 months.
-
What Do Analysts Say About Summit Therapeutics?
Analysts are divided on their view about Summit Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Summit Therapeutics is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Summit Therapeutics's Price Target?
The price target for Summit Therapeutics over the next 1-year time period is forecast to be $37.19 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SMMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Summit Therapeutics is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SMMT?
You can purchase shares of Summit Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Summit Therapeutics shares.
-
What Is The Summit Therapeutics Share Price Today?
Summit Therapeutics was last trading at $23.61 per share. This represents the most recent stock quote for Summit Therapeutics. Yesterday, Summit Therapeutics closed at $24.11 per share.
-
How To Buy Summit Therapeutics Stock Online?
In order to purchase Summit Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
